Questions have emerged about whether the DEA's revised approach to synthetic and concentrated 7-OH products goes far enough. Could manufacturers find ways around the limits? Will forensic laboratories be able to enforce them? And does keeping natural kratom outside Schedule I leave a gap in public safety?
These are fair questions, especially for law enforcement agencies responsible for keeping dangerous substances off the streets.
Fortunately, the DEA and the Department of Health and Human Services (HHS) have already looked closely at these concerns. Their revised approach is built on a scientific review aimed at stopping dangerous manufactured opioids without sweeping natural kratom into the same category
There's more than one safeguard
One concern is that manufacturers could simply add water or sugar to concentrated 7-OH products to get around federal limits.
It sounds like a loophole. But the DEA's October 14 proposal includes two separate tests, not just one.
The first measures how much 7-OH or mitragynine pseudoindoxyl (MP) is present in a product. The second compares those compounds to mitragynine, the main alkaloid found in natural kratom.
A product that fails either test would be subject to Schedule I controls under the proposal.
For example, a 12-ounce beverage containing 355 milligrams of 7-OH would need at least 35.5 grams of mitragynine to meet the proposed ratio requirement, assuming no MP is present. Simply adding water or sugar wouldn't change that.
It's an important detail, and one that makes the proposed limits harder to get around than they might first appear.
Natural kratom is a different story
Natural kratom has a very different makeup from manufactured, concentrated 7-OH products. Its primary alkaloid is mitragynine, and it naturally contains much smaller amounts of 7-OH.
That distinction isn't just an industry argument. It's reflected in the scientific review behind the federal proposal.
Research continues to support looking at natural kratom separately. A 2026 controlled human study reported that botanical kratom was generally well tolerated at the doses tested, with no serious adverse events under the study conditions.
HHS considered the available science before making its recommendation, and the DEA used that work to develop its revised approach.
The goal is to stop dangerous manufactured opioids without unnecessarily restricting a botanical product that deserves to be judged on its own merits.
Give law enforcement the tools to enforce it
Testing is another legitimate concern. Measuring individual compounds takes more work than simply identifying whether a substance is present.
But this isn't an unsolvable problem. Recent forensic research involving NMS Labs scientists has demonstrated methods for measuring these compounds separately.
Some laboratories may need additional equipment, training, or access to specialized testing. Those are practical needs that can be addressed.
If better testing is what law enforcement needs to enforce the rules, that's where the effort should go. The difficulty of a test isn't, by itself, a reason to ban an entire botanical plant.
The DEA and HHS have done the scientific work to draw a meaningful line between natural kratom and dangerous manufactured opioid products. Their approach leaves room for responsible consumer protections while giving law enforcement a clearer target.
Protecting the public doesn't have to mean treating every product associated with kratom the same way.
The federal agencies have provided a sound foundation. The next step is making sure law enforcement has the tools to put it to work.
Comments